Lundbeck (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Lundbeck" in English language version.

refsWebsite

Global rank English rank

5lundbeck.com

low place

4web.archive.org

1^st place

2fiercepharma.com

low place

8,921^st place

2genengnews.com

low place

6,625^th place

2reuters.com

49^th place

47^th place

1shareholder.com

6,233^rd place

5,563^rd place

1thepharmaletter.com

low place

1glgroup.com

low place

1cphpost.dk

low place

7,678^th place

1wsj.com

79^th place

65^th place

1chicagobusiness.com

4,398^th place

2,433^rd place

1texasarrests.org

low place

1europa.eu

68^th place

117^th place

chicagobusiness.com

"Akorn acquires controversial drug, two others from Danish firm". chicagobusiness.com. 22 December 2011. Retrieved August 6, 2022.

cphpost.dk

"Execution drug still available after Lundbeck shuns 'end user' agreements". The Copenhagen Post. 1 April 2011. Archived from the original on 7 August 2011. Retrieved 3 July 2011.

europa.eu

ec.europa.eu

"Press corner". European Commission - European Commission.

fiercepharma.com

"Lundbeck replaces retiring CEO Dunsire with UCB exec after breaking sales record". 27 June 2023. Retrieved 2023-06-27.
Liu, Angus (2 July 2018). "Ex-Millennium chief Deborah Dunsire looks for pipeline growth as Lundbeck's CEO". FiercePharma. Retrieved 4 July 2018.

genengnews.com

"H. Lundbeck Acquiring Chelsea Therapeutics for Up to $658M". May 8, 2014.
"Lundbeck to Acquire Prexton Therapeutics for Up-to-$1.1B". 16 March 2018.

glgroup.com

"Lundbeck's "Serotonin Modulator and Stimulator" Lu AA21004: How Novel? How Good? - GLG News".

lundbeck.com

"Facts and background". lundbeck.com. Retrieved 2021-04-07.
"Wayback Machine" (PDF). 2021-06-11. Archived from the original (PDF) on 2021-06-11. Retrieved 2023-01-25.
"Facts and background". lundbeck.com. Retrieved 2021-04-07.
"Shareholder Composition and Dividends".
"Sabril (vigabatrin) Tablets. Prescribing information." Lundbeck Inc., 2012. Revised February 2012. "Archived copy" (PDF). Archived from the original (PDF) on 2013-01-20. Retrieved 2013-02-07.{{cite web}}: CS1 maint: archived copy as title (link)

reuters.com

uk.reuters.com

"Lundbeck buys Alder for $2 billion, eyes 'blockbuster' migraine therapy". Reuters. September 16, 2019 – via uk.reuters.com.

reuters.com

"Special Report: How the Trump administration secured a secret supply of execution drugs". reuters.com. 10 July 2020. Retrieved August 6, 2022.

shareholder.com

files.shareholder.com

H. Lundbeck A/S (December 14, 2012). "Corporate Release No 487. Lundbeck to divest a portfolio of non-core products as part of its strategy to focus on newer, strategic CNS-products" (PDF). Archived from the original (PDF) on 3 March 2016. Retrieved 29 July 2014.

texasarrests.org

"Texas is Running Out of Execution Drug". texasarrests.org. Retrieved August 6, 2022.

thepharmaletter.com

"Lundbeck initiates CEO succession". www.thepharmaletter.com. Retrieved 2023-06-27.

web.archive.org

"Wayback Machine" (PDF). 2021-06-11. Archived from the original (PDF) on 2021-06-11. Retrieved 2023-01-25.
H. Lundbeck A/S (December 14, 2012). "Corporate Release No 487. Lundbeck to divest a portfolio of non-core products as part of its strategy to focus on newer, strategic CNS-products" (PDF). Archived from the original (PDF) on 3 March 2016. Retrieved 29 July 2014.
"Sabril (vigabatrin) Tablets. Prescribing information." Lundbeck Inc., 2012. Revised February 2012. "Archived copy" (PDF). Archived from the original (PDF) on 2013-01-20. Retrieved 2013-02-07.{{cite web}}: CS1 maint: archived copy as title (link)
"Execution drug still available after Lundbeck shuns 'end user' agreements". The Copenhagen Post. 1 April 2011. Archived from the original on 7 August 2011. Retrieved 3 July 2011.

wsj.com

"Lundbeck Seeks to Curb Use of Drug in Executions". The Wall Street Journal. 1 July 2011. Retrieved 3 July 2011.